Vimarsana
Biggest News Aggregation in the World

Multiple Sclerosis Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Sclerosis Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Program Today - Breaking & Trending Today

Dr. Rhonda Voskuhl receives award for innovative multiple sclerosis research - Vimarsana News

Dr. Rhonda Voskuhl receives award for innovative multiple sclerosis research

The professor is being recognized by the National Multiple Sclerosis Society and the American Academy of Neurology.

Source: ucla.edu
UCLA Health Neurologist Receives Award for Innovative Multiple Sclerosis Research - Vimarsana News

UCLA Health Neurologist Receives Award for Innovative Multiple Sclerosis Research

Dr. Rhonda Voskuhl, a professor of neurology at UCLA Health, has been awarded the 2024 John Dystel Prize for Multiple Sclerosis Research in recognition of her o

Blood test may lower risk of disability in children with MS: Lancet - Vimarsana News

Blood test may lower risk of disability in children with MS: Lancet

USA: A recent study published in The Lancet Neurology has revealed that an experimental method developed to detect nerve injury in multiple sclerosis (MS) in adults also works for children with MS and...

UCSF Study Finds Blood Test May Reduce Risk of Disability in Kids - Vimarsana News

UCSF Study Finds Blood Test May Reduce Risk of Disability in Kids

An experimental method developed to detect nerve injury in multiple sclerosis (MS) in adults also works for children with MS and other neurological conditions, even when they are symptom-free, according to an international team of researchers. In MS,

Tolebrutinib associated with long-term safety, efficacy in relapsing-remitting MS - Vimarsana News

Tolebrutinib associated with long-term safety, efficacy in relapsing-remitting MS

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.“In the MS field, we need treatments that can better target both peripheral and centrally mediated inflammation, and I think there is a lot of hope for

Source: healio.com